A pharmacodynamic study of JI-101, an orally active inhibitor of VEGF-2, PDGF-β, and EphB4 receptors, in patients with refractory/recurrent ovarian cancer.
Theresa Louise Werner
Research Funding - Vanthys
Aaron Lynn Luebke
No relevant relationships to disclose
Mark Wade
No relevant relationships to disclose
Nuggehally R Srinivas
Employment or Leadership Position - Vanthys
Consultant or Advisory Role - Vanthys
Dhiraj J. Abhyankar
Employment or Leadership Position - Vanthys
Consultant or Advisory Role - Vanthys
Philip Caligiuri
No relevant relationships to disclose
Marta Elise Heilbrun
No relevant relationships to disclose
Sunil Sharma
Research Funding - Jubilant Pharmaceuticals; Vanthys